US › Healthcare

Insight Molecular Diagnostics Inc. (IMDX)

US · Healthcare · Diagnostics & Research

$3.95+10.34%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$239,000

Revenue YoY

-53.9%

Net profit

$-11.3M

EPS

$-0.23

EPS estimate

$-0.23

Net margin

-4,711.3%

EPS came in at -0.23 against a street estimate of -0.23 — a beat of 0.0%.

Key statistics

Market cap

$137.4M

Forward P/E

0.0

P/B

87.06

Book value

$-0.65

EPS (TTM)

$-1.52

52-week high

$8.51

52-week low

$2.42

50-day MA

$4.56

200-day MA

$5.21

Beta

1.80

Analyst view

with an average price target of $8.25.

Shareholding

Insiders

21.00%

Institutions

56.43%

Largest institutional holders

Fund	Stake
BROADWOOD CAPITAL Inc	38.88%
Awm Investment Company Inc	8.60%
Alyeska Investment Group, L.P.	2.58%
Vanguard Capital Management, LLC	1.65%
PURA VIDA INVESTMENTS, LLC	1.49%
Heights Capital Management Inc	1.20%
Geode Capital Management, LLC	0.80%
FNY Investment Advisers, LLC	0.76%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Insight Molecular Diagnostics Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.